Telix Pharmaceuticals Limited American Depositary Shares
TLXDividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| May 2, 2006 | $0.04 | 2006-04-18 | 2006-04-20 |
| January 31, 2006 | $0.04 | 2006-01-11 | 2006-01-16 |
| October 28, 2005 | $0.04 | 2005-10-05 | 2005-10-07 |
| July 15, 2005 | $0.04 | 2005-06-21 | 2005-06-23 |
| April 29, 2005 | $0.04 | 2005-04-18 | 2005-04-20 |
Dividends Summary
- Consistent Payer: Telix Pharmaceuticals Limited American Depositary Shares has rewarded shareholders with 10 dividend payments over the past 2 years.
- Total Returned Value: Investors who held TLX shares during this period received a total of $0.35 per share in dividend income.
- Latest Payout: The most recent dividend of $0.04/share was paid 7382 days ago, on May 2, 2006.
- Yield & Schedule: TLX currently pays dividends quarterly with an annual yield of 1.34%.
- Dividend Growth: Since 2004, the dividend payout has grown by 0.0%, from $0.04 to $0.04.
- Dividend Reliability: TLX has maintained or increased its dividend for 10 consecutive payments.
Company News
Telix Pharmaceuticals announced successful alignment with the FDA on the Part 2 protocol design of its ProstACT Global Phase 3 trial for TLX591-Tx in metastatic castration resistant prostate cancer. The FDA confirmed that Part 1 safety data is sufficient to progress Part 2 into the U.S., where the therapeutic candidate will be tested in combinati...
Telix Pharmaceuticals announced an educational webinar scheduled for June 29-30, 2026, featuring clinical updates on neuro-oncology and theranostics approaches to address unmet needs in glioma and glioblastoma treatment. The webinar will include presentations from Telix's Chief Medical Officer and fireside chats with leading nuclear medicine and ...
Over 200 companies are advancing 220+ pipeline glioblastoma drugs across various clinical development stages. The pipeline is shifting from conventional chemotherapy toward targeted therapy, immunotherapy, and epigenetic approaches. Key candidates include Kazia Therapeutics' Paxalisib (Phase III), BPG Bio's BPM31510, and immunotherapy programs fr...
The metastatic prostate cancer market is projected to experience robust growth through 2036, valued at USD 11.5 billion in 2025 across seven major markets. The market is transitioning from conventional androgen deprivation therapy toward combination-based, biomarker-driven approaches, with novel therapies such as PSMA-targeted radioligand therapi...
Telix Pharmaceuticals announced positive Phase 3 Part 1 data for TLX591-Tx, a lutetium radio antibody-drug conjugate for metastatic castration-resistant prostate cancer. The study of 36 patients showed acceptable safety and tolerability when combined with standard-of-care therapies, with no new safety signals. Radiation exposure remained below es...
